In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aurobindo receives tentative FDA OK for abacavir sulfate/lamivudine

This article was originally published in Scrip

Executive Summary

Aurobindo Pharmahas received tentative approval from the US FDAto manufacture and market abacavir sulfate/lamivudine tablets 600mg/300mg, a generic version of GlaxoSmithKline's Epzicom tablets. The product was reviewed under the President's emergency plan for AIDS relief (PEPFAR), Aurobindo informed the Bombay Stock Exchange. The product represents Aurobindo's 76th ANDA approval by the FDA.

You may also be interested in...



Tripartite Avigan Alliance Aims For Global Access

Fujifilm Toyama seals three-way deal to accelerate the development and global supply of favipiravir, close on the heels of the arrival of a generic version of the antiviral in India under restricted emergency use for the treatment of COVID-19.

Glenmark Sanguine On Ichnos Capital Raise Plan Amid Mixed Dermatitis Data

Glenmark’s innovation spin-out initiates efforts to raise capital in the US, unfazed by mixed top-line results for its investigational atopic dermatitis treatment. Its parent firm has underscored the value proposition of the oncology franchise and proprietary bispecific antibody technology platform.

COVID-19 Unveils Social Media Might: Is Pharma Listening Hard Enough?

COVID-19 has generated a mind-boggling one billion-plus mentions on social media, unleashing unstructured big data rich in insights. Experts explain why pharma may well want  to“listen in” more raptly to such conversations across therapy areas while shaping some aspects of business strategy.

Topics

Related Companies

UsernamePublicRestriction

Register

LL082593

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel